These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 29156043)

  • 1. Tenofovir Alafenamide Fumarate: A New Tenofovir Prodrug for the Treatment of Chronic Hepatitis B Infection.
    Buti M; Riveiro-Barciela M; Esteban R
    J Infect Dis; 2017 Nov; 216(suppl_8):S792-S796. PubMed ID: 29156043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    Chan HL; Fung S; Seto WK; Chuang WL; Chen CY; Kim HJ; Hui AJ; Janssen HL; Chowdhury A; Tsang TY; Mehta R; Gane E; Flaherty JF; Massetto B; Gaggar A; Kitrinos KM; Lin L; Subramanian GM; McHutchison JG; Lim YS; Acharya SK; Agarwal K;
    Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):185-195. PubMed ID: 28404091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
    Agarwal K; Brunetto M; Seto WK; Lim YS; Fung S; Marcellin P; Ahn SH; Izumi N; Chuang WL; Bae H; Sharma M; Janssen HLA; Pan CQ; Çelen MK; Furusyo N; Shalimar D; Yoon KT; Trinh H; Flaherty JF; Gaggar A; Lau AH; Cathcart AL; Lin L; Bhardwaj N; Suri V; Mani Subramanian G; Gane EJ; Buti M; Chan HLY; ;
    J Hepatol; 2018 Apr; 68(4):672-681. PubMed ID: 29756595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial.
    Post FA; Yazdanpanah Y; Schembri G; Lazzarin A; Reynes J; Maggiolo F; Yan M; Abram ME; Tran-Muchowski C; Cheng A; Rhee MS
    HIV Clin Trials; 2017 May; 18(3):135-140. PubMed ID: 28303753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
    Fong TL; Lee BT; Tien A; Chang M; Lim C; Ahn A; Bae HS
    J Viral Hepat; 2019 May; 26(5):561-567. PubMed ID: 30576085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy.
    Ogawa E; Furusyo N; Nguyen MH
    Drug Des Devel Ther; 2017; 11():3197-3204. PubMed ID: 29158666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate.
    Kaneko S; Kurosaki M; Tamaki N; Itakura J; Hayashi T; Kirino S; Osawa L; Watakabe K; Okada M; Wang W; Shimizu T; Higuchi M; Takaura K; Yasui Y; Tsuchiya K; Nakanishi H; Takahashi Y; Watanabe M; Izumi N
    J Gastroenterol Hepatol; 2019 Nov; 34(11):2004-2010. PubMed ID: 31017689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate.
    Byun KS; Choi J; Kim JH; Lee YS; Lee HC; Kim YJ; Yoo BC; Kwon SY; Gwak GY; Lim YS
    Clin Gastroenterol Hepatol; 2022 Feb; 20(2):427-437.e5. PubMed ID: 33962041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load.
    Li B; Liu Z; Liu X; Liu D; Duan M; Gu Y; Liu Q; Ma Q; Wei Y; Wang Y
    Hepatol Int; 2021 Oct; 15(5):1103-1108. PubMed ID: 34312798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV.
    Pan CQ; Chang TT; Bae SH; Brunetto M; Seto WK; Coffin CS; Tan SK; Mo S; Flaherty JF; Gaggar A; Nguyen MH; Çelen MK; Thompson A; Gane EJ
    PLoS One; 2021; 16(5):e0251552. PubMed ID: 33984038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection.
    Abdul Basit S; Dawood A; Ryan J; Gish R
    Expert Rev Clin Pharmacol; 2017 Jul; 10(7):707-716. PubMed ID: 28460547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved Bone Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate Over 2 Years in Patients With Chronic HBV Infection.
    Seto WK; Asahina Y; Brown TT; Peng CY; Stanciu C; Abdurakhmanov D; Tabak F; Nguyen TT; Chuang WL; Inokuma T; Ikeda F; Santantonio TA; Habersetzer F; Ramji A; Lau AH; Suri V; Flaherty JF; Wang H; Gaggar A; Subramanian GM; Mukewar S; Brunetto MR; Fung S; Chan HL
    Clin Gastroenterol Hepatol; 2018 Jun; ():. PubMed ID: 29933096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics.
    Hsu YC; Wei MT; Nguyen MH
    Expert Rev Gastroenterol Hepatol; 2017 Nov; 11(11):999-1008. PubMed ID: 28965428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B.
    Lee HW; Cho YY; Lee H; Lee JS; Kim SU; Park JY; Kim DY; Ahn SH; Kim BK; Park SY
    J Viral Hepat; 2021 Nov; 28(11):1570-1578. PubMed ID: 34435412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions?
    Viganò M; Loglio A; Grossi G; Lampertico P
    Expert Rev Anti Infect Ther; 2018 Feb; 16(2):153-161. PubMed ID: 29338458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nucleos(t)ide analogue therapy: The role of tenofovir alafenamide.
    Buti M; Marcos-Fosch C; Esteban R
    Liver Int; 2021 Jun; 41 Suppl 1():9-14. PubMed ID: 34155802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015-2017.
    Gomez M; Seybold U; Roider J; Härter G; Bogner JR
    Infection; 2019 Feb; 47(1):95-102. PubMed ID: 30269210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B.
    Suzuki K; Suda G; Yamamoto Y; Abiko S; Kinoshita K; Miyamoto S; Sugiura R; Kimura M; Maehara O; Yamada R; Kitagataya T; Shigesawa T; Ohara M; Kawagishi N; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N
    PLoS One; 2022; 17(1):e0261760. PubMed ID: 35051189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Epi-TAF for Tenofovir Disoproxil Fumarate?
    Walensky RP; Horn TH; Paltiel AD
    Clin Infect Dis; 2016 Apr; 62(7):915-8. PubMed ID: 26658300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Converting from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Patients with Hepatitis B Following Liver Transplantation.
    Cheng CH; Hung HC; Lee JC; Wang YC; Wu TH; Lee CF; Wu TJ; Chou HS; Chan KM; Lee WC
    Ann Transplant; 2023 Apr; 28():e938731. PubMed ID: 37081752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.